Literature DB >> 33388910

Subjects with coronary artery disease and reduced ejection fraction have longer (GT)n repeats in the heme-oxygenase 1 gene promoter.

Kae-Woei Liang1,2, Wen-Jane Lee3,4, Wen-Lieng Lee5,6, Jen-Pey Wu3, I-Te Lee6,7, Jun-Sing Wang6,7, Wayne H-H Sheu6,7,8,9.   

Abstract

Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT)n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data (N = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% (N = 256), and mid-range EF 40-49% (N = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) (p < 0.001). The patients with reduced EF had a significantly longer average (GT)n (median 27.5 vs. 26.5, p = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT)n repeats than those with mid-range EF.

Entities:  

Keywords:  Coronary artery disease (CAD); Heart failure with reduced ejection fraction; Heme oxygenase (HO)-1; Promoter polymorphism

Year:  2021        PMID: 33388910     DOI: 10.1007/s00380-020-01733-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  3 in total

1.  The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.

Authors:  Georgios Sianos; Marie-Angèle Morel; Arie Pieter Kappetein; Marie-Claude Morice; Antonio Colombo; Keith Dawkins; Marcel van den Brand; Nic Van Dyck; Mary E Russell; Friedrich W Mohr; Patrick W Serruys
Journal:  EuroIntervention       Date:  2005-08       Impact factor: 6.534

2.  Heme oxygenase-1 in inflammation and cardiovascular disease.

Authors:  Meng-Ling Wu; Yen-Chun Ho; Chen-Yu Lin; Shaw-Fang Yet
Journal:  Am J Cardiovasc Dis       Date:  2011-07-28

3.  Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light.

Authors:  R F Furchgott; D Jothianandan
Journal:  Blood Vessels       Date:  1991
  3 in total
  3 in total

Review 1.  Heme Oxgenase-1, a Cardinal Modulator of Regulated Cell Death and Inflammation.

Authors:  Stefan W Ryter
Journal:  Cells       Date:  2021-02-28       Impact factor: 6.600

Review 2.  Association between HO‑1 gene promoter polymorphisms and diseases (Review).

Authors:  Lin-Lin Ma; Lei Sun; Yu-Xi Wang; Bai-He Sun; Yan-Fei Li; Yue-Ling Jin
Journal:  Mol Med Rep       Date:  2021-11-29       Impact factor: 2.952

Review 3.  Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders.

Authors:  Stefan W Ryter
Journal:  Antioxidants (Basel)       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.